

Rinat Yerushalmi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/584452/publications.pdf>

Version: 2024-02-01

71
papers

2,252
citations

567281

15
h-index

223800

46
g-index

74
all docs

74
docs citations

74
times ranked

3391
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-11-16: Rate of breast biopsy referrals in <i>BRCA</i> mutation carriers: A retrospective comparative study and matched analysis. Cancer Research, 2022, 82, P2-11-16-P2-11-16.	0.9	0
2	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. Cancer Research, 2022, 82, PD8-01-PD8-01.	0.9	4
3	Abstract P2-09-16: Clinicopathological features and outcome of breast cancer in CHEK2 germline mutation carriers. Cancer Research, 2022, 82, P2-09-16-P2-09-16.	0.9	0
4	Abstract P5-13-08: Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study. Cancer Research, 2022, 82, P5-13-08-P5-13-08.	0.9	0
5	Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry. Cancer Research, 2022, 82, P1-08-14-P1-08-14.	0.9	0
6	Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis. Breast Cancer Research and Treatment, 2022, , 1.	2.5	0
7	Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.. Journal of Clinical Oncology, 2022, 40, 565-565.	1.6	0
8	Timing to imaging and surgery after neoadjuvant therapy for breast cancer. Clinical Imaging, 2021, 71, 24-28.	1.5	3
9	A novel role for an old target: CD45 for breast cancer immunotherapy. Oncoimmunology, 2021, 10, 1929725.	4.6	12
10	Abstract PS1-50: Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis. , 2021, , .		0
11	Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3369-3379.	2.5	21
12	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. Breast Cancer Research and Treatment, 2021, 188, 379-387.	2.5	3
13	COVID-19 in a patient receiving adjuvant breast cancer chemotherapy with granulocyte colony-stimulating factor (G-CSF) support: A case report. Molecular and Clinical Oncology, 2021, 14, 117.	1.0	1
14	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. JAMA Oncology, 2021, 7, 573.	7.1	217
15	Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer.. Journal of Clinical Oncology, 2021, 39, e18791-e18791.	1.6	0
16	Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. Frontiers in Medicine, 2021, 8, 675963.	2.6	6
17	Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis. Breast, 2021, 58, 173-181.	2.2	23
18	The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer. Discover Oncology, 2021, 12, 26.	2.1	2

#	ARTICLE	IF	CITATIONS
19	The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer. <i>Oncology</i> , 2021, 99, 713-721.	1.9	0
20	Genetic testing in patients with triple-negative or hereditary breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 584-590.	2.4	1
21	Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. <i>Breast</i> , 2021, 60, 62-69.	2.2	88
22	Diagnostic workup of early-stage breast cancer: can we choose more wisely?. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 741-748.	2.5	2
23	Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity"From Bench to Bedside. <i>Biomedicines</i> , 2020, 8, 577.	3.2	8
24	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	7.7	4
25	Ethnicity, recurrence score distribution, and clinical outcomes in ER+HER2-negative breast cancer patients in Israel: A registry analysis. <i>Breast Journal</i> , 2020, 26, 2096-2098.	1.0	2
26	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. <i>Cancer Medicine</i> , 2020, 9, 4603-4612.	2.8	3
27	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 259-266.	2.5	0
28	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz085.	2.9	24
29	GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment. <i>BMC Cancer</i> , 2020, 20, 333.	2.6	7
30	Cardiotoxicity manifestations in metastatic breast cancer patients treated with trastuzumab as first line.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13011-e13011.	1.6	1
31	Recurrence score (RS) differences between primary and second-primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12587-e12587.	1.6	0
32	3,3'-Diindolylmethane (DIM): A nutritional intervention and its impact on breast density in healthy BRCA carriers compared to non-treated carriers" A prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1556-1556.	1.6	0
33	The impact of exogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e12606-e12606.	1.6	0
34	The impact of endogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e12605-e12605.	1.6	0
35	The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 231-237.	2.5	7
36	Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz033.	2.9	20

#	ARTICLE	IF	CITATIONS
37	Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.3	3
38	Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling. <i>Oncology</i> , 2019, 96, 14-24.	1.9	10
39	Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1071-1071.	1.6	1
40	De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 524-524.	1.6	0
41	Investigating the utility of breast cancer (BC) molecular signatures and immune signature profiling (ISP) as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy + trastuzumab (NAC+T) in HER2+ BC.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12109-e12109.	1.6	0
42	Hormone replacement therapy (HRT) and risk of distant recurrence in newly diagnosed ER+, node-negative (N-) breast-cancer (BC) patients: A retrospective population-based matched-cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6591-6591.	1.6	0
43	Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2- Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial. <i>Clinical Breast Cancer</i> , 2018, 18, e197-e203.	2.4	10
44	Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion. <i>Clinical Breast Cancer</i> , 2018, 18, e267-e270.	2.4	18
45	Comparison of background parenchymal enhancement and fibroglandular density at breast magnetic resonance imaging between BRCA gene mutation carriers and non-carriers. <i>Clinical Imaging</i> , 2018, 51, 347-351.	1.5	6
46	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	27.0	1,472
47	EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1069-1069.	1.6	4
48	Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1070-1070.	1.6	8
49	Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?. <i>Oncotarget</i> , 2018, 9, 15931-15941.	1.8	32
50	A prospective long term follow up of pulmonary diffusion capacity reduction caused by dose dense chemotherapy in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12537-e12537.	1.6	0
51	Prognostic value of the detection of lympho-vascular invasion in hormone receptor positive early breast cancer in the era of molecular profiling.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12539-e12539.	1.6	0
52	The association between smoking and breast cancer characteristics and outcome. <i>BMC Cancer</i> , 2017, 17, 624.	2.6	25
53	The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-9.	1.5	5
54	Perception of prognosis of cancer patients by non-oncologists. <i>International Journal of Clinical Practice</i> , 2016, 70, 1027-1032.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?. Breast Journal, 2016, 22, 662-666.	1.0	3
56	Invasive Lobular Carcinoma of the Breast: Appearance on Digital Breast Tomosynthesis. Breast Care, 2016, 11, 359-362.	1.4	10
57	BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2016, 7, 2433-2454.	1.8	19
58	The association between antihypertensive medications and breast cancer characteristics.. Journal of Clinical Oncology, 2016, 34, e12000-e12000.	1.6	0
59	Malignancy associated SIADH: Characterization and clinical implications.. Journal of Clinical Oncology, 2016, 34, e21622-e21622.	1.6	0
60	Premature ovarian aging in <i>BRCA</i> carriers: Is it a prototype of systemic precocious aging?. Journal of Clinical Oncology, 2016, 34, e13016-e13016.	1.6	0
61	The association between treatment for metabolic disorders and breast cancer characteristics.. Journal of Clinical Oncology, 2016, 34, 527-527.	1.6	1
62	A Dedicated Follow-Up Clinic for BRCA Mutation Carriers. Israel Medical Association Journal, 2016, 18, 549-552.	0.1	5
63	Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer. Oncology Letters, 2015, 10, 2149-2155.	1.8	30
64	Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study. PLoS ONE, 2015, 10, e0138229.	2.5	7
65	Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity. Oncologist, 2015, 20, 985-991.	3.7	33
66	Oncotype-DX recurrence score distribution among breast cancer patients harboring a germline mutation in the BRCA1/2 genes.. Journal of Clinical Oncology, 2015, 33, 564-564.	1.6	0
67	Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 & 12 in Breast Cancer Patients: A Retrospective Analysis. PLoS ONE, 2014, 9, e107273.	2.5	7
68	Pharmacological induction of cell surface GRP78 contributes to apoptosis in triple negative breast cancer cells. Oncotarget, 2014, 5, 11452-11463.	1.8	35
69	Chemotherapy-induced ovarian failure in young breast cancer patients: The role of vascular toxicity.. Journal of Clinical Oncology, 2014, 32, 9595-9595.	1.6	0
70	Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic growth colony stimulating factor (G-CSF) on days 8 and 12 in breast cancer patients: A retrospective analysis.. Journal of Clinical Oncology, 2012, 30, 202-202.	1.6	0
71	Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. Journal of Surgical Oncology, 2006, 93, 529-533.	1.7	37